Mark Haygood, DO
Psychiatry · Mobile, ALNPI 1073834370
Payments from drug & device makers
Across 1,322 payments — averaging $263.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$171K
- Neurocrine Biosciences, Inc.$149K
- Otsuka America Pharmaceutical, Inc.$18K
- Teva Pharmaceuticals USA, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Axsome Therapeutics, Inc.$844
- plus $6K from 26 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 599 | $171,329 |
| Neurocrine Biosciences, Inc. | 195 | $149,486 |
| Otsuka America Pharmaceutical, Inc. | 130 | $17,949 |
| Teva Pharmaceuticals USA, Inc. | 60 | $2,049 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 46 | $1,058 |
| Axsome Therapeutics, Inc. | 30 | $844 |
| Johnson & Johnson | 29 | $820 |
| Takeda Pharmaceuticals U.S.A., Inc. | 41 | $621 |
| Vanda Pharmaceuticals Inc. | 37 | $619 |
| Supernus Pharmaceuticals, Inc. | 22 | $580 |
| E.r. Squibb & Sons, L.L.C. | 27 | $496 |
| Neuronetics, Inc. | 7 | $397 |
| Lundbeck LLC | 18 | $326 |
| Sunovion Pharmaceuticals Inc. | 3 | $242 |
| Abbott | 8 | $165 |
| Alkermes, Inc. | 9 | $165 |
| Stryker | 1 | $150 |
| Jazz Pharmaceuticals Inc. | 7 | $118 |
| Adlon Therapeutics L.p. | 7 | $117 |
| Shire North American Group Inc | 10 | $111 |
| Corium, LLC | 8 | $110 |
| Eisai Inc. | 5 | $85 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 5 | $81 |
| OWP Pharmaceuticals, Inc. | 3 | $58 |
| Avanir Pharmaceuticals, Inc. | 3 | $47 |
| Bausch Health US, LLC | 2 | $46 |
| Neos Therapeutics, LP | 2 | $43 |
| Tris Pharma Inc | 2 | $39 |
| Acadia Pharmaceuticals Inc | 2 | $30 |
| Arbor Pharmaceuticals, Inc. | 2 | $25 |
| Alfasigma USA, Inc. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
How this compares
$348,236 in reported general payments places this provider in the 95th percentile of 400 psychiatry providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other psychiatry in Mobile
- Bradley SadlerMobile$124K
- Michael MarshallMobile$59K
- Mary Cohen ColsonMobile$10K
- Lucas BooneMobile$10K
- Bradley BrooksMobile$6K
- Sandra ParkerMobile$5K
- Matthew MacalusoBirmingham$2.8M
- Richard SheltonBirmingham$2.4M
- Michael FalolaTrussville$2.2M
- Armand SchachterBirmingham$758K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.